About Prosarix
Prosarix is a company based in Cambridge (United Kingdom) founded in 2006 was acquired by RxCelerate in February 2019. Prosarix offers products and services including ProtoDiscovery™ Platform, RxNfinity™, and Virtual Screening. Prosarix operates in a competitive market with competitors including Insitro, HotSpot Therapeutics, TOLREMO therapeutics, Certara and Inpharmatica, among others.
- Headquarter Cambridge, United Kingdom
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Prosarix Uk Ltd
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
-
Investors
Evolva
& 1 more
-
Employee Count
Not available
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Prosarix
Prosarix offers a comprehensive portfolio of products and services, including ProtoDiscovery™ Platform, RxNfinity™, and Virtual Screening.
Facilitates rapid identification and optimization of small molecules and biologics.
Explores vast chemical spaces for novel compound identification.
Screens compounds for potential drug targets efficiently.
Funding Insights of Prosarix
Detailed funding history for Prosarix
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Prosarix
Prosarix has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Evolva and RxCelerate.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Pre-clinical contract research services are offered for drug candidates.
|
Locked | Locked | Locked | |
|
Producer of natural and functional ingredients for food, beverage and healthcare products
|
Locked | Locked | Locked |
Investor details for Prosarix
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Prosarix
Investment portfolio details for Prosarix
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Prosarix
Detailed financials for Prosarix
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Prosarix Comparisons
Peer comparison for Prosarix
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Prosarix
Prosarix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, HotSpot Therapeutics, TOLREMO therapeutics, Certara and Inpharmatica, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Developer of a platform for protein function analysis
|
|
| Locked | Locked | Locked |
Anti-cancer small molecules are developed to target drug resistance pathways.
|
|
| Locked | Locked | Locked |
Provider of a platform for in silico drug discovery and consulting services
|
|
| Locked | Locked | Locked |
Developer of predictive informatics based platform for drug discovery
|
|
| Locked | Locked | Locked |
Immune system-based drugs are discovered via biological data analytics.
|
Detailed competitors of Prosarix
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Prosarix
Complete news archive for Prosarix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Prosarix
Prosarix was founded in 2006.
Prosarix is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Prosarix Ltd is a UK-based computational drug discovery company with a proprietary platform for drug screening and design. Their proprietary ProtoDiscovery platformsuite can be used for the identification and optimisation of small molecule ligands to specific targets. The suite contains three structure-based technologies namely ProtoScore(Proprietary Scoring function), ProtoScreen(for virtual screening), ProtoBuild (Small molecule de novo design tool) and two ligand-based technologies. ProtoShapeES (Electrostatic and molecule shape-based screening), ProtoClassify (Ligand classification using pharmacophore features). The company also has ProtoDiscovery Compound Database (PCD), which has a library of gt;5M compounds for screening. The company also offers EnzaCore SAR Explorer Panels, a set of products that can be used for the incorporation of chiral building blocks. Prosarix has an in-house discovery program focused on GPCR targets to identify and develop novel lead series for CNS. Prosarix claims that its advanced lead candidates from its in-house program have shown pre-clinical efficacy in models of pain, anxiety and depression. Prosarix was formed in 2007 following the acquisition of the platform from Amura Holdings.
Prosarix's top competitors include Insitro, HotSpot Therapeutics and Certara.
Prosarix offers ProtoDiscovery™ Platform, RxNfinity™, and Virtual Screening.
Prosarix has 2 investors. Key investors include Evolva, and RxCelerate.